Community and Civil Society Engagement Case Studies
Here we feature the work and achievements of community and civil society organizations funded under ASCENT DR-TB CCSE program.
Finding New Hope through the BPaL/M Regimen in Sleman, Yogyakarta, Indonesia
Written by: Yayasan Penyintas Tuberkulosis TERBESAR Yogyakarta (TERBESAR) A 50-year-old woman from Sleman District, Yogyakarta Special Region, was diagnosed with drug-resistant tuberculosis (DR-TB) on March 30, 2024. She lives with five other family members, making a total of six people…
Strengthening DR-TB Management and Access to Care through Strategic Advocacy and Community Engagement in Nasarawa State, Nigeria
Drug-resistant tuberculosis (DR-TB) continues to pose a significant public health challenge in Nigeria. Despite advancements in treatment regimens, access to quality care, trained personnel, and patient follow-up remain major barriers to effective DR-TB control, especially in semi-urban and rural areas.
Work with TAG: Programmatic Communications Coordinator
TAG is hiring! We are looking for a dynamic, experienced communications coordinator to work closely with our tuberculosis (TB) project team. Learn more and apply here!
Where Science Meets Justice: Before Most of Us Wake Up, TAG is Already Defending HIV Progress
Treatment Action Group’s (TAG) HIV team works across the country to achieve a shared mission: end the HIV epidemic through science, policy, and advocacy. As a remote team, the reach is national but the urgency is personal. At a time when progress is possible and precarious, the team ensures that research translates into action for impacted communities.
The Path Forward: TAG’s Vision for HIV, TB, and Hepatitis C
TAG's leadership and staff broke down the latest in HIV, TB, and hepatitis C research and advocacy. See where the work stands and where it's headed.
TAG Statement on Results of the PreVenTB Phase III Trial of TB Vaccine Candidates VPM1002 and Immuvac
Well-conducted study sponsored by Indian Council of Medical Research did not meet primary efficacy endpoint of preventing microbiologically confirmed TB disease
The CDC’s Unjustified Halt on Testing for Dangerous Pathogens is Bad for Everyone’s Health – TAG Calls for CDC to Immediately Reinstate Essential Diagnostic Testing
CDC pauses rabies, mpox, and other infectious disease testing amid budget cuts and staffing losses, raising urgent public health concerns.
TAG Public Comments for the AIDS Research Advisory Council (ARAC) Meeting, April 6, 2026: Renewing Funding for the HIV Clinical Trial Networks
TAG recommends that the AIDS Research Advisory Council (ARAC) endorse NIAID's continued support of a balanced and comprehensive portfolio of basic, clinical, and implementation science — including a funding opportunity to renew its four current networks: the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG), the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), the HIV Prevention Trials Network (HPTN), and the HIV Vaccine Trials Network (HVTN) or the updated IBPTN.
Near Point-of-Care TB Tests: What Communities Need to Know and Advocate for in Global Fund Grant Cycle 8
TB testing is getting faster, cheaper, and more accessible and advocates have a critical window to act. Treatment Action Group's new factsheet breaks down WHO-recommended near point-of-care TB tests and shows how communities can use Global Fund Grant Cycle 8 to finance their rollout. With an estimated 2.7 million people going undiagnosed in 2024 alone, the tools and funding are finally aligned. Now is the time to push for change.